LIBRETTO-001

NCT03157128 📎

Regimen

Experimental
selpercatinib
Control
none

Population

RET fusion+ NSCLC

Key finding

Pretreated ORR 64% (54-73); tx-naive ORR 85%; mDOR 17.5 mo

Source: PMID 32846060

Timeline

  • Enrollment start: 2017-05-02 📎

Guideline citations

  • CSCO NSCLC 2025 ⚠️ OCR source